Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years. NICE technology appraisal guidance 554
National Institute for Health and Care Excellence (NICE)
Record ID 32018011619
English
Details
Project Status:
Completed
URL for project:
https://www.nice.org.uk/guidance/ta554
Year Published:
2018
URL for published report:
https://www.nice.org.uk/guidance/ta554
English language abstract:
An English language summary is available
Publication Type:
Full HTA
Country:
England
MeSH Terms
- Young Adult
- Immunotherapy, Adoptive
- Receptors, Chimeric Antigen
- Receptors, Antigen, T-Cell
- Adolescent
- Child
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Contact
Organisation Name:
National Institute for Health and Care Excellence
Contact Address:
Level 1A, City Tower, Piccadilly Plaza, Manchester, M1 4BT
Contact Name:
nice@nice.nhs.uk
Contact Email:
nice@nice.nhs.uk
Copyright:
National Institute for Health and Care Excellence (NICE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.